Blog

Cushing Syndrome (Study Outline) For study only—this is not medical advice or a substitute for professional care. 1. Background Definition:A disorder caused by prolonged exposure to elevated glucocorticoids (cortisol), whether from endogenous overproduction or exogenous administration. Terminology: Cushing syndrome: the clinical state of cortisol excess (any cause). Cushing disease: specifically from an ACTH-secreting pituitary adenoma. Pathophysiology: ACTH-dependent: Pituitary adenoma (Cushing disease, ~70% of endogenous cases). Ectopic ACTH secretion (e.g., small cell lung carcinoma). ACTH-independent: Adrenal adenoma or carcinoma. Exogenous corticosteroids (most common overall). Cortisol excess → ↑ gluconeogenesis, protein catabolism, lipolysis, and mineralocorticoid activity → metabolic, cardiovascular, and immune effects. Epidemiology: More common in women aged 20–50 years for endogenous disease. Exogenous corticosteroid use is the leading cause overall. 2. History Gradual onset over months to years. Typical Symptoms: Weight gain (central/truncal). Fatigue, weakness, depression, irritability. Menstrual irregularities, decreased libido. Headache or vision changes (pituitary tumor). Metabolic/Endocrine: Glucose intolerance or diabetes. Hypertension, osteoporosis, edema. Physical Appearance (classic triad): Truncal obesity, moon facies, buffalo hump. Other Findings: Purple (>1 cm) abdominal striae, easy bruising, thin skin, poor wound healing. Hirsutism and acne (from adrenal androgens). 3. Exam Findings General: Central obesity with thin limbs, proximal muscle wasting. Skin: Fragile skin, violaceous striae, acne, easy bruising. HEENT: Facial rounding, plethora, supraclavicular fat pads. CV: Hypertension, possible edema. Neuropsych: Depression, insomnia, irritability. Reproductive: Decreased libido, menstrual changes, infertility. 4. Making the Diagnosis Step 1 – Confirm Hypercortisolism (screening): 24-hour urinary free cortisol: elevated. Late-night salivary cortisol: elevated. Low-dose dexamethasone suppression test: failure to suppress cortisol confirms Cushing syndrome. Step 2 – Determine ACTH Dependence: Low ACTH: adrenal tumor or exogenous steroids. High/normal ACTH: pituitary adenoma or ectopic ACTH source. Step 3 – Identify the Source: High-dose dexamethasone suppression test: Pituitary (Cushing disease): partial suppression. Ectopic ACTH: no suppression. CRH stimulation test: Pituitary: ACTH rises. Ectopic: no response. Imaging: Pituitary MRI for suspected adenoma. CT chest/abdomen for ectopic or adrenal tumors. Gold Standard: Demonstration of hypercortisolism via ≥2 positive screening tests, followed by ACTH level determination and localization studies. 5. Management (Exam Concepts) (Conceptual overview only—no dosing or treatment regimens.) Iatrogenic (exogenous steroids): gradual taper of glucocorticoids. Cushing disease (pituitary adenoma): transsphenoidal surgical resection. Adrenal adenoma/carcinoma: adrenalectomy. Ectopic ACTH tumor: surgical resection if possible; medical suppression if unresectable. Medical therapy (for refractory disease): Steroidogenesis inhibitors (ketoconazole, metyrapone, mitotane). Glucocorticoid receptor antagonist (mifepristone). Postoperative care: monitor for adrenal insufficiency and hormone replacement needs. Complications: hypertension, diabetes, osteoporosis, infections, psychiatric symptoms. Exam Tips: Most common cause overall: exogenous corticosteroids. Most common endogenous cause: pituitary adenoma. Ectopic ACTH: severe hypokalemia, rapid onset, hyperpigmentation. Adrenal tumor: low ACTH, unilateral adrenal mass. NBME-Style Practice Question A 39-year-old woman presents with progressive weight gain, fatigue, and easy bruising. She has a rounded face, dorsocervical fat pad, and violaceous abdominal striae. Laboratory testing reveals elevated urinary free cortisol and failure to suppress cortisol on a low-dose dexamethasone suppression test. Plasma ACTH is elevated. Which of the following tests best distinguishes a pituitary from an ectopic source of ACTH? A. Serum DHEA-S levelB. High-dose dexamethasone suppression testC. MRI of the adrenal glandsD. 24-hour urinary metanephrine level

Thyroid Cancer (Study Outline) For study only—this is not medical advice or a substitute for professional care. 1. Background Definition:Malignant tumors arising from thyroid follicular or parafollicular cells, varying from indolent to aggressive behavior. Epidemiology: Most common endocrine malignancy. Women > men; peak incidence 30–50 years. Excellent prognosis for differentiated cancers (papillary, follicular). Major Types (High-Yield): Type % Cell Origin Key Features Papillary carcinoma 80–85% Follicular cells Most common; lymphatic spread; prior radiation risk; excellent prognosis. Follicular carcinoma 10–15% Follicular cells Hematogenous spread (bone/lung); requires invasion for diagnosis. Medullary carcinoma 3–5% Parafollicular (C) cells Produces calcitonin; MEN 2A/2B association. Anaplastic carcinoma

Hypoglycemia (Study Outline) For study only—this is not medical advice or a substitute for professional care. 1. Background Definition:Blood glucose level

Diabetic Ketoacidosis (DKA) (Study Outline) For study only—this is not medical advice or a substitute for professional care. 1. Background Definition: Acute, life-threatening metabolic complication of diabetes mellitus characterized by: Hyperglycemia Ketosis Anion gap metabolic acidosis Pathophysiology: Absolute or relative insulin deficiency + increased counter-regulatory hormones (glucagon, cortisol, catecholamines, growth hormone). Promotes lipolysis → free fatty acids → ketone body production (β-hydroxybutyrate, acetoacetate). Leads to osmotic diuresis, dehydration, and electrolyte loss. Epidemiology: More common in Type 1 diabetes, but can occur in Type 2 diabetes under stress. Precipitating Factors: Infection (most common) Missed insulin doses Myocardial infarction, stroke, pancreatitis, trauma, or surgery Certain medications (e.g., glucocorticoids, SGLT2 inhibitors) 2. History Rapid onset (hours to days). Classic symptoms: Polyuria, polydipsia, dehydration. Nausea, vomiting, abdominal pain. Shortness of breath (Kussmaul respirations). Fatigue, confusion, fruity (acetone) breath. Historical clues: Recent illness, skipped insulin, new-onset Type 1 diabetes. History of poor glycemic control or insulin pump malfunction. 3. Exam Findings Vital Signs: Tachycardia, tachypnea, hypotension, fever (if infectious trigger). General: Dehydration: dry mucous membranes, poor skin turgor. Kussmaul respirations: deep, labored breathing due to metabolic acidosis. Fruity odor on breath (acetone). Neurologic: Lethargy, confusion, possible coma in severe cases. Abdominal: Tenderness and pain common due to acidosis (may mimic acute abdomen). 4. Making the Diagnosis Diagnostic Triad: Hyperglycemia: Glucose typically >250 mg/dL Metabolic acidosis: Arterial pH 600), minimal ketones, no significant acidosis. 5. Management (Exam Concepts) (Conceptual overview only—no dosing or real-world directives.) Immediate priorities: Restore intravascular volume (IV fluids are first step). Correct electrolyte abnormalities (especially potassium). Administer insulin to suppress ketogenesis and correct acidosis. Identify and treat precipitating cause (infection, missed insulin, etc.). Monitoring: Hourly glucose checks. Frequent electrolytes (especially potassium and bicarbonate). Watch for cerebral edema, especially in children. Transition to long-term care: Once anion gap closes and patient can tolerate PO intake, transition to subcutaneous insulin. Complications to Recognize: Hypokalemia after insulin therapy. Cerebral edema (more common in pediatric DKA). ARDS or shock in severe dehydration QUESTION A 17-year-old girl with type 1 diabetes presents with nausea, vomiting, and rapid breathing. She reports missing several insulin doses. Physical exam reveals tachycardia, dry mucous membranes, and deep, labored respirations. Laboratory results show glucose 440 mg/dL, bicarbonate 12 mEq/L, and positive serum ketones. Which of the following best explains her acid-base disturbance? A. Lactic acid accumulation from hypoxiaB. Ketone body production due to insulin deficiencyC. Bicarbonate loss from vomitingD. Increased CO₂ retention due to respiratory depression  

Hashimoto Thyroiditis (Chronic Lymphocytic Thyroiditis) (Study Outline) For study only—this is not medical advice or a substitute for professional care. 1. Background Definition:Autoimmune destruction of the thyroid gland leading to chronic hypothyroidism.It is the most common cause of primary hypothyroidism in iodine-sufficient regions (e.g., the U.S.). Pathophysiology: Autoantibodies target thyroid antigens, primarily thyroid peroxidase (anti-TPO) and thyroglobulin (anti-Tg). Lymphocytic infiltration with formation of germinal centers leads to gradual destruction of thyroid tissue. Over time → decreased T₄/T₃ synthesis, elevated TSH, and permanent thyroid failure. Early in disease, transient thyrotoxicosis (“Hashitoxicosis”) can occur due to release of preformed thyroid hormones. Epidemiology: Most common in middle-aged women (30–60 years). Associated with other autoimmune disorders: type 1 diabetes, Addison disease, pernicious anemia, celiac disease, vitiligo. Genetic predisposition: linked to HLA-DR3 and HLA-DR5. 2. History Typical Symptoms (Gradual Onset): Fatigue, weight gain, cold intolerance. Constipation, dry skin, hair loss, brittle nails. Depression, slowed thinking, memory issues. Menstrual irregularities, infertility. Voice changes, neck fullness, dysphagia (from goiter). Early “Hashitoxicosis” Phase: Transient symptoms of hyperthyroidism (anxiety, heat intolerance, palpitations) due to hormone leakage from damaged follicles. Historical Clues: Family history of autoimmune thyroid disease. Previous thyroid enlargement (“goiter”) followed by gradual slowing of metabolism. 3. Exam Findings General: Tired appearance, weight gain, dry coarse hair and skin. Thyroid Exam: Firm, rubbery, non-tender, diffusely enlarged thyroid in early stages. May become atrophic over time due to fibrosis. Skin: Cool, pale, dry. Cardiovascular: Bradycardia, diastolic hypertension. Neurologic: Delayed relaxation of deep tendon reflexes. HEENT: Puffy face, periorbital edema, hoarse voice (from myxedema). Late Stage: Myxedema signs, macroglossia, and generalized slowing of activity. 4. Making the Diagnosis Initial Test (Gold Standard): Serum TSH — elevated (primary hypothyroidism). Confirmatory Findings: ↓ Free T₄, sometimes ↓ T₃. Positive anti-thyroid peroxidase (anti-TPO) and/or anti-thyroglobulin (anti-Tg) antibodies → diagnostic hallmark. Additional Laboratory Findings: Mild hypercholesterolemia (due to reduced LDL clearance). Normocytic or macrocytic anemia. Hyponatremia possible due to impaired free water excretion. Imaging (if indicated): Thyroid ultrasound: diffuse heterogeneity and hypoechogenicity (“moth-eaten” appearance). Fine-needle aspiration (FNA): lymphocytic infiltration, Hurthle cells (oncocytic metaplasia). Diagnostic Pattern: ↑ TSH + ↓ T₄ + positive anti-TPO antibodies = Hashimoto thyroiditis. 5. Management (Exam Concepts) (Conceptual overview only—no dosing or treatment regimens.) General Principle: Thyroid hormone replacement (levothyroxine) for symptomatic or overt hypothyroidism. Monitoring: Reassess TSH every 6–8 weeks after initiating or adjusting therapy. Once stable, check annually. Complications: Myxedema coma: life-threatening hypothyroid crisis in severe, untreated disease. Goiter enlargement may cause local compressive symptoms. Increased risk of thyroid lymphoma (especially if longstanding Hashimoto’s). Exam Tips: Firm, painless goiter + anti-TPO antibodies → classic for Hashimoto thyroiditis. Thyroiditis progression: transient thyrotoxic phase → euthyroid → permanent hypothyroid. Differentiate from subacute thyroiditis: Hashimoto is painless and chronic; subacute is painful and self-limited.   QUESTION A 42-year-old woman presents with fatigue, weight gain, and cold intolerance. Physical exam reveals a firm, non-tender, diffusely enlarged thyroid gland. Laboratory results show TSH 11.2 mIU/L (elevated) and free T₄ below normal. Which of the following findings would most likely confirm the diagnosis? A. Positive thyroid-stimulating immunoglobulins (TSI)B. Positive anti–thyroid peroxidase (anti-TPO) antibodiesC. Decreased serum thyroglobulin concentrationD. Diffuse increased radioactive iodine uptake  

Paget Disease of Bone (Osteitis Deformans) (Study Outline) For study only—this is not medical advice or a substitute for professional care. 1. Background Definition:Chronic skeletal disorder caused by disorganized bone remodeling—excessive bone resorption followed by chaotic bone formation—resulting in enlarged, deformed, and weak bone. Pathophysiology: Overactive osteoclasts → excessive bone breakdown. Compensatory osteoblastic activity → disorganized, sclerotic new bone (mosaic pattern). Affected bone is hypervascular, structurally weak, and prone to fractures. Commonly involves pelvis, skull, spine, femur, tibia. Etiology: Unknown; likely genetic (SQSTM1 mutations) or viral (paramyxovirus) triggers. Epidemiology: Onset usually after age 50, more common in men. Higher prevalence in European descent. Often asymptomatic, discovered incidentally via elevated alkaline phosphatase (ALP). 2. History Asymptomatic in up to 80%. Symptomatic findings: Bone pain (most common symptom; dull, aching, worse at night). Skeletal deformities: Skull enlargement (“increasing hat size”), frontal bossing. Bowing of long bones (femur, tibia). Hearing loss (CN VIII compression from skull involvement). Fractures: transverse (“chalk-stick”) fractures in long bones. Warmth over affected bone (due to increased vascularity). Complications: Osteoarthritis (bone deformity near joints). High-output heart failure (rare, from increased vascularity). Osteosarcoma (rare malignant transformation). Historical Clues: Older adult with bone pain + elevated ALP + normal calcium. Hearing loss or increasing hat size = classic clue. 3. Exam Findings General: Often normal; may show deformities or tenderness. Skull: Frontal bossing, craniofacial enlargement, hearing loss. Spine: Kyphosis or spinal stenosis (nerve compression). Extremities: Bowing of legs (anterolateral tibial curvature), increased warmth. CV: In advanced disease, signs of high-output cardiac failure. 4. Making the Diagnosis Laboratory Findings: Test Result Alkaline phosphatase (ALP) ↑↑ (high bone turnover) Calcium Normal Phosphate Normal PTH Normal Urinary hydroxyproline ↑ (bone collagen breakdown) Imaging: X-ray (diagnostic hallmark): Early: osteolytic (“blade of grass” or “flame-shaped”) lesions. Mixed phase: patchy sclerosis and cortical thickening. Late: dense, enlarged bone with deformity. Skull: “cotton wool” appearance. Bone scan: Increased uptake in affected bones—maps disease extent. Diagnostic Pattern: Elevated ALP with normal calcium and phosphate + characteristic radiologic findings. Gold Standard: X-ray evidence of mixed lytic–sclerotic lesions + elevated ALP. 5. Management (Exam Concepts) (Conceptual overview only—no dosing or treatment regimens.) 1. Asymptomatic Patients: Observation if no pain or deformity and ALP stable. 2. Symptomatic or Active Disease: First-line: Bisphosphonates (e.g., alendronate, zoledronic acid) → inhibit osteoclasts. Second-line: Calcitonin (less potent, used if bisphosphonates contraindicated). Pain management: NSAIDs or acetaminophen for bone pain. Calcium and vitamin D supplementation to prevent hypocalcemia during treatment. 3. Complications Management: Orthopedic surgery: for fractures, severe deformity, or arthritis. Hearing aids for auditory loss. Monitor ALP levels for treatment response and recurrence.   QUESTION A 72-year-old man presents to his primary care clinic with a complaint of increasing right hip discomfort over the past few months. He denies recent trauma. His medical history includes hypertension and type 2 diabetes. He does not take corticosteroids. He reports difficulty hearing from his right ear and occasional headaches. Physical examination reveals mild anterior bowing of the right tibia and decreased range of motion in the right hip. Laboratory studies show: Serum calcium: 9.4 mg/dL (8.6–10.2) Phosphate: 3.1 mg/dL (2.5–4.5) Alkaline phosphatase: 430 U/L (40–129) PTH: 42 pg/mL (10–65) Which of the following is the most appropriate next step in management? A) Reassurance and observationB) Oral bisphosphonate therapyC) Serum 25-hydroxyvitamin D levelD) Total body bone scintigraphy  

Paget Disease of Bone (Osteitis Deformans) (Study Outline) For study only—this is not medical advice or a substitute for professional care. 1. Background Definition:Chronic skeletal disorder caused by disorganized bone remodeling—excessive bone resorption followed by chaotic bone formation—resulting in enlarged, deformed, and weak bone. Pathophysiology: Overactive osteoclasts → excessive bone breakdown. Compensatory osteoblastic activity → disorganized, sclerotic new bone (mosaic pattern). Affected bone is hypervascular, structurally weak, and prone to fractures. Commonly involves pelvis, skull, spine, femur, tibia. Etiology: Unknown; likely genetic (SQSTM1 mutations) or viral (paramyxovirus) triggers. Epidemiology: Onset usually after age 50, more common in men. Higher prevalence in European descent. Often asymptomatic, discovered incidentally via elevated alkaline phosphatase (ALP). 2. History Asymptomatic in up to 80%. Symptomatic findings: Bone pain (most common symptom; dull, aching, worse at night). Skeletal deformities: Skull enlargement (“increasing hat size”), frontal bossing. Bowing of long bones (femur, tibia). Hearing loss (CN VIII compression from skull involvement). Fractures: transverse (“chalk-stick”) fractures in long bones. Warmth over affected bone (due to increased vascularity). Complications: Osteoarthritis (bone deformity near joints). High-output heart failure (rare, from increased vascularity). Osteosarcoma (rare malignant transformation). Historical Clues: Older adult with bone pain + elevated ALP + normal calcium. Hearing loss or increasing hat size = classic clue. 3. Exam Findings General: Often normal; may show deformities or tenderness. Skull: Frontal bossing, craniofacial enlargement, hearing loss. Spine: Kyphosis or spinal stenosis (nerve compression). Extremities: Bowing of legs (anterolateral tibial curvature), increased warmth. CV: In advanced disease, signs of high-output cardiac failure. 4. Making the Diagnosis Laboratory Findings: Test Result Alkaline phosphatase (ALP) ↑↑ (high bone turnover) Calcium Normal Phosphate Normal PTH Normal Urinary hydroxyproline ↑ (bone collagen breakdown) Imaging: X-ray (diagnostic hallmark): Early: osteolytic (“blade of grass” or “flame-shaped”) lesions. Mixed phase: patchy sclerosis and cortical thickening. Late: dense, enlarged bone with deformity. Skull: “cotton wool” appearance. Bone scan: Increased uptake in affected bones—maps disease extent. Diagnostic Pattern: Elevated ALP with normal calcium and phosphate + characteristic radiologic findings. Gold Standard: X-ray evidence of mixed lytic–sclerotic lesions + elevated ALP. 5. Management (Exam Concepts) (Conceptual overview only—no dosing or treatment regimens.) 1. Asymptomatic Patients: Observation if no pain or deformity and ALP stable. 2. Symptomatic or Active Disease: First-line: Bisphosphonates (e.g., alendronate, zoledronic acid) → inhibit osteoclasts. Second-line: Calcitonin (less potent, used if bisphosphonates contraindicated). Pain management: NSAIDs or acetaminophen for bone pain. Calcium and vitamin D supplementation to prevent hypocalcemia during treatment. 3. Complications Management: Orthopedic surgery: for fractures, severe deformity, or arthritis. Hearing aids for auditory loss. Monitor ALP levels for treatment response and recurrence.   QUESTION A 72-year-old man presents to his primary care clinic with a complaint of increasing right hip discomfort over the past few months. He denies recent trauma. His medical history includes hypertension and type 2 diabetes. He does not take corticosteroids. He reports difficulty hearing from his right ear and occasional headaches. Physical examination reveals mild anterior bowing of the right tibia and decreased range of motion in the right hip. Laboratory studies show: Serum calcium: 9.4 mg/dL (8.6–10.2) Phosphate: 3.1 mg/dL (2.5–4.5) Alkaline phosphatase: 430 U/L (40–129) PTH: 42 pg/mL (10–65) Which of the following is the most appropriate next step in management? A) Reassurance and observationB) Oral bisphosphonate therapyC) Serum 25-hydroxyvitamin D levelD) Total body bone scintigraphy  

Graves Disease (Study Outline) For study only—this is not medical advice or a substitute for professional care. 1. Background Definition:An autoimmune disorder causing primary hyperthyroidism due to TSH receptor–stimulating antibodies (thyroid-stimulating immunoglobulins, TSI) that mimic TSH and overstimulate the thyroid gland. Pathophysiology: Autoantibodies bind and activate TSH receptors on thyroid follicular cells → ↑ synthesis and release of T₄ (thyroxine) and T₃ (triiodothyronine). Persistent stimulation → thyroid hyperplasia (diffuse goiter) and systemic thyrotoxicosis. Extrathyroidal manifestations (eye and skin changes) result from autoimmune inflammation and glycosaminoglycan deposition in orbital and dermal tissues. Epidemiology: Most common cause of hyperthyroidism in the U.S. Predominantly affects women (8:1 ratio), peak incidence ages 20–40 years. Associated with other autoimmune diseases (e.g., type 1 DM, pernicious anemia, vitiligo). Triggers: Stress, infection, postpartum period, smoking, and excessive iodine exposure. 2. History Symptoms of Hyperthyroidism: Palpitations, tachycardia, heat intolerance, diaphoresis. Weight loss despite normal/increased appetite. Tremor, anxiety, insomnia, hyperactivity. Frequent bowel movements or diarrhea. Fatigue, muscle weakness. Oligomenorrhea, infertility. Specific Graves Features: Ophthalmopathy: eye irritation, diplopia, proptosis (exophthalmos), lid lag, conjunctival injection. Dermopathy: pretibial myxedema — thickened, hyperpigmented skin over the shins. Goiter symptoms: neck fullness or pressure, dysphagia (if large). May report family history of thyroid or autoimmune disease. 3. Exam Findings General: Warm, moist skin; fine hair; hyperkinesis. Vital Signs: Tachycardia, widened pulse pressure, possible atrial fibrillation. Thyroid Exam: Diffuse, symmetric, non-tender enlargement with possible bruit (due to increased vascularity). Ophthalmopathy: Exophthalmos, periorbital edema, chemosis, lid lag, proptosis. Severe cases: exposure keratitis or optic neuropathy. Dermopathy: Pretibial myxedema: localized, nonpitting, thickened skin with “peau d’orange” texture on shins. Neurologic: Fine tremor, hyperreflexia. Elderly: “Apathetic” Graves disease — minimal hyperactivity, fatigue, or weight loss only. 4. Making the Diagnosis Screening and Confirmation: ↓ TSH, ↑ free T₄ and/or T₃ (primary hyperthyroidism pattern). Specific Tests: Positive TSH receptor antibodies (TRAb) or thyroid-stimulating immunoglobulins (TSI): confirm Graves disease. Radioactive Iodine Uptake (RAIU) Scan: Diffuse increased uptake → classic for Graves. Thyroid Ultrasound (if nodules suspected): diffuse vascularity (“thyroid inferno” on Doppler). Other Labs/Findings: Elevated alkaline phosphatase (bone turnover). Mild hypercalcemia. Normal or elevated thyroglobulin. Gold Standard for Diagnosis: Positive TSH receptor antibodies (TRAb/TSI) with diffuse increased RAI uptake in a hyperthyroid patient. 5. Management (Exam Concepts) (Conceptual overview only—no dosing or clinical directives.) Goals: Control thyrotoxic symptoms, inhibit hormone production, and prevent complications. 1. Symptom Control: β-blockers (e.g., propranolol): alleviate tremor, tachycardia, anxiety. 2. Antithyroid Medications: Thionamides (e.g., methimazole, propylthiouracil): inhibit thyroid hormone synthesis (PTU also blocks peripheral T₄→T₃ conversion). Used for mild disease, pregnancy, or before definitive therapy. 3. Definitive Therapies: Radioactive iodine ablation (RAI): most common definitive treatment; destroys overactive thyroid tissue. Thyroidectomy: for large goiters, compressive symptoms, or contraindications to RAI/medication. 4. Ophthalmopathy Management: Smoking cessation (reduces risk and progression). Glucocorticoids for severe inflammation. Ophthalmology referral for vision-threatening disease. 5. Special Situations: Thyroid storm: life-threatening hypermetabolic crisis; requires ICU-level care with aggressive supportive measures. Pregnancy: PTU preferred in 1st trimester, methimazole in later trimesters (exam concept). Monitoring: Recheck thyroid function (TSH and free T₄) every 4–8 weeks during titration. Watch for hypothyroidism after RAI or surgery (may require lifelong hormone replacement).     QUESTION A 28-year-old woman presents with palpitations, weight loss, and heat intolerance. Exam reveals a diffusely enlarged thyroid with bruit, fine tremor, and bilateral exophthalmos. Labs show TSH

Graves Disease (Study Outline) For study only—this is not medical advice or a substitute for professional care. 1. Background Definition:An autoimmune disorder causing primary hyperthyroidism due to TSH receptor–stimulating antibodies (thyroid-stimulating immunoglobulins, TSI) that mimic TSH and overstimulate the thyroid gland. Pathophysiology: Autoantibodies bind and activate TSH receptors on thyroid follicular cells → ↑ synthesis and release of T₄ (thyroxine) and T₃ (triiodothyronine). Persistent stimulation → thyroid hyperplasia (diffuse goiter) and systemic thyrotoxicosis. Extrathyroidal manifestations (eye and skin changes) result from autoimmune inflammation and glycosaminoglycan deposition in orbital and dermal tissues. Epidemiology: Most common cause of hyperthyroidism in the U.S. Predominantly affects women (8:1 ratio), peak incidence ages 20–40 years. Associated with other autoimmune diseases (e.g., type 1 DM, pernicious anemia, vitiligo). Triggers: Stress, infection, postpartum period, smoking, and excessive iodine exposure. 2. History Symptoms of Hyperthyroidism: Palpitations, tachycardia, heat intolerance, diaphoresis. Weight loss despite normal/increased appetite. Tremor, anxiety, insomnia, hyperactivity. Frequent bowel movements or diarrhea. Fatigue, muscle weakness. Oligomenorrhea, infertility. Specific Graves Features: Ophthalmopathy: eye irritation, diplopia, proptosis (exophthalmos), lid lag, conjunctival injection. Dermopathy: pretibial myxedema — thickened, hyperpigmented skin over the shins. Goiter symptoms: neck fullness or pressure, dysphagia (if large). May report family history of thyroid or autoimmune disease. 3. Exam Findings General: Warm, moist skin; fine hair; hyperkinesis. Vital Signs: Tachycardia, widened pulse pressure, possible atrial fibrillation. Thyroid Exam: Diffuse, symmetric, non-tender enlargement with possible bruit (due to increased vascularity). Ophthalmopathy: Exophthalmos, periorbital edema, chemosis, lid lag, proptosis. Severe cases: exposure keratitis or optic neuropathy. Dermopathy: Pretibial myxedema: localized, nonpitting, thickened skin with “peau d’orange” texture on shins. Neurologic: Fine tremor, hyperreflexia. Elderly: “Apathetic” Graves disease — minimal hyperactivity, fatigue, or weight loss only. 4. Making the Diagnosis Screening and Confirmation: ↓ TSH, ↑ free T₄ and/or T₃ (primary hyperthyroidism pattern). Specific Tests: Positive TSH receptor antibodies (TRAb) or thyroid-stimulating immunoglobulins (TSI): confirm Graves disease. Radioactive Iodine Uptake (RAIU) Scan: Diffuse increased uptake → classic for Graves. Thyroid Ultrasound (if nodules suspected): diffuse vascularity (“thyroid inferno” on Doppler). Other Labs/Findings: Elevated alkaline phosphatase (bone turnover). Mild hypercalcemia. Normal or elevated thyroglobulin. Gold Standard for Diagnosis: Positive TSH receptor antibodies (TRAb/TSI) with diffuse increased RAI uptake in a hyperthyroid patient. 5. Management (Exam Concepts) (Conceptual overview only—no dosing or clinical directives.) Goals: Control thyrotoxic symptoms, inhibit hormone production, and prevent complications. 1. Symptom Control: β-blockers (e.g., propranolol): alleviate tremor, tachycardia, anxiety. 2. Antithyroid Medications: Thionamides (e.g., methimazole, propylthiouracil): inhibit thyroid hormone synthesis (PTU also blocks peripheral T₄→T₃ conversion). Used for mild disease, pregnancy, or before definitive therapy. 3. Definitive Therapies: Radioactive iodine ablation (RAI): most common definitive treatment; destroys overactive thyroid tissue. Thyroidectomy: for large goiters, compressive symptoms, or contraindications to RAI/medication. 4. Ophthalmopathy Management: Smoking cessation (reduces risk and progression). Glucocorticoids for severe inflammation. Ophthalmology referral for vision-threatening disease. 5. Special Situations: Thyroid storm: life-threatening hypermetabolic crisis; requires ICU-level care with aggressive supportive measures. Pregnancy: PTU preferred in 1st trimester, methimazole in later trimesters (exam concept). Monitoring: Recheck thyroid function (TSH and free T₄) every 4–8 weeks during titration. Watch for hypothyroidism after RAI or surgery (may require lifelong hormone replacement).     QUESTION A 28-year-old woman presents with palpitations, weight loss, and heat intolerance. Exam reveals a diffusely enlarged thyroid with bruit, fine tremor, and bilateral exophthalmos. Labs show TSH

You are caring for a 62-year-old patient admitted to the ICU with severe pneumonia. The patient is on mechanical ventilation with an FiO₂ of 0.60 (60%) with 10cmH20 of PEEP. The arterial blood gas (ABG) shows: pH: 7.32 PaCO₂: 52 mmHg PaO₂: 75 mmHg Chest X-ray shows bilateral pulmonary infiltrates, and a pulmonary capillary wedge pressure (PCWP) of 10 mmHg is recorded. Question: Based on this information, what is the most likely diagnosis?